1
|
Wang Y, Quan Q, Gleason C, Yu H, Peng L, Kang Y, Jiang L, Wu K, Pan J, Bao M, Zhu Q, Yi M, Fang M, Zheng Y, Qiu L, Xu B, Li X, Song J, Sun J, Zhang Z, Su Z, Lin J, Xie Y, Xu A, Song X, Huang C, Shen Z, Wang L, Song J. Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies. MAbs 2023; 15:2292305. [PMID: 38095560 DOI: 10.1080/19420862.2023.2292305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Accepted: 12/04/2023] [Indexed: 12/18/2023] Open
Abstract
Pharmaceutical companies have recently focused on accelerating the timeline for initiating first-in-human (FIH) trials to allow quick assessment of biologic drugs. For example, a stable cell pool can be used to produce materials for the toxicology (Tox) study, reducing time to the clinic by 4-5 months. During the coronavirus disease 2019 (COVID-19) pandemic, the anti-COVID drugs timeline from DNA transfection to the clinical stage was decreased to 6 months using a stable pool to generate a clinical drug substrate (DS) with limited stability, virus clearance, and Tox study package. However, a lean chemistry, manufacturing, and controls (CMC) package raises safety and comparability risks and may leave extra work in the late-stage development and commercialization phase. In addition, whether these accelerated COVID-19 drug development strategies can be applied to non-COVID projects and established as a standard practice in biologics development is uncertain. Here, we present a case study of a novel anti-tumor drug in which application of "fast-to-FIH" approaches in combination with BeiGene's de-risk strategy achieved successful delivery of a complete CMC package within 10 months. A comprehensive comparability study demonstrated that the DS generated from a stable pool and a single-cell-derived master cell bank were highly comparable with regards to process performance, product quality, and potency. This accomplishment can be a blueprint for non-COVID drug programs that approach the pace of drug development during the pandemic, with no adverse impact on the safety, quality, and late-stage development of biologics.
Collapse
Affiliation(s)
- Yuqi Wang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Quan Quan
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Camille Gleason
- Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USA
| | - Helin Yu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Lujia Peng
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yanshen Kang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ling Jiang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Kailun Wu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jie Pan
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Moxiyele Bao
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Qing Zhu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Meiqi Yi
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ming Fang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yue Zheng
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ling Qiu
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Bin Xu
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Xiang Li
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Jinfeng Song
- Department of Technical Operation and Manufacturing, BeiGene (Guangzhou) Co. Ltd, Guangzhou, China
| | - Jiamu Sun
- Department of Regulatory Affairs CMC, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Zheng Zhang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Zijun Su
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jara Lin
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yuanyuan Xie
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - April Xu
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Xiling Song
- Department of Regulatory Affairs CMC, BeiGene USA, Inc, San Mateo, CA, USA
| | - Chichi Huang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Zhirong Shen
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Lai Wang
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jing Song
- Department of Research and Development, BeiGene (Beijing) Co. Ltd, Beijing, China
| |
Collapse
|